

Table SII. Clinicopathological characteristics of 112 patients with early-stage PDAC from The Cancer Genome Atlas database.

Variable	Patients (n=12)	Overall survival			
		Number of events	Median survival time (months)	HR (95% CI)	Log-rank P
Age (years)					
≤60	38	20	593	1	0.066
>60	74	49	485	1.636 (0.962-2.780)	
Missing	0				
Gender					
Female	53	36	511	1	0.523
Male	59	33	592	0.855 (0.529-1.382)	
Missing	0				
Alcohol history ^b					
NO	43	25	592	1	0.349
YES	61	38	511	1.276 (0.765-2.128)	
Missing	8				
History of chronic pancreatitis					
NO	79	47	511	1	0.478
YES	9	7	607	1.335 (0.600-2.970)	
Missing	24				
Tumor size ^d					
≤2	4	1	NA	1	0.708
>2 and ≤4	76	47	511	2.266 (0.311-16.498)	
>4	30	21	592	2.202 (0.294-16.474)	
Missing	2				
Pathological stage					
I-II	8	4	236	1	0.943
III-IV	104	65	518	1.038 (0.375-2.872)	
Missing	0				
Neoplasm histological grade					
G1+G2	80	45	596	1	0.010
G3+G4	32	24	470	2.267 (0.962-5.341)	
Missing	0				
Targeted molecular therapy					
NO	29	24	224	1	<0.001
YES	73	41	634	1.068 (0.095-0.296)	
Missing	10				
Radiation therapy					
NO	70	48	473	1	0.029
YES	30	15	691	0.527 (0.293-0.947)	
Missing	12				
Residual resection					

R0	66	39	63	1	
R1+R2	44	29	381	1.945 (1.174-3.223)	0.009
Missing	2				

PDAC, pancreatic ductal adenocarcinoma; HR, hazard ratio; CI, confidence interval.